Wolman originally described this condition between 1956 and 1961 as a cause of chronic diarrhea associated with calcification of the adrenal glands. 1, 2 In 1972, acid lipase deficiency was detected in fibroblasts. 3 Fatty inclusions in the gastrointestinal tract cause the severe diarrhea. There is massive systemic accumulation of triglycerides and cholesterol. Cirrhosis of the liver ensues. Pulmonary infiltration results from lipid deposition. Death occurs during infancy. 4 Therapeutic attempts have included intravenous alimentation, plasma infusion, corticosteroids, and dietary supplementation of various types. All of these have failed to provide relief except for short periods of time.
The rationale for using bone marrow transplantation was first considered subsequent to the demonstration that exogenous acid lipase enters lysosomes of abnormal fibroblasts. This cross-correction caused these fibroblasts to become normal. 3 Further support was obtained after bone marrow transplantation in the murine model of this disease demonstrated correction of serum acid lipase enzyme activity. 5 Based on these concepts we have shown that bone marrow transplantation corrects the leukocyte lysosomal acid lipase deficiency following donor-derived engraftment. 6, 7 Unfortunately, four transplanted patients died due to disease and/or bone marrow transplant complications.
The patient reported here was transplanted relatively early in the course of the disease and has remained engrafted with donor-derived hematopoietic cells for 3. years. The diarrhea gradually decreased and bowel movements are now normal. Hepatic function has normalized, and cholesterol and triglyceride plasma levels are normal. There is no hepatosplenomegaly. This case report emphasizes the importance of timely diagnosis and the potential for successful treatment of Wolman disease by bone marrow transplantation.
Patients and methods
The older brother of our patient developed diarrhea, weight loss, and inanition at the age of 1 month and subsequently died by 3 months of age. He had adrenal gland calcifications, vacuolated lymphocytes, and deficient acid lipase enzyme activity in peripheral leukocytes and fibroblasts. Pathologic analysis of the liver revealed extensive cholesterol deposits. Autopsy confirmed the diagnosis of Wolman syndrome, noting adrenal gland calcifications and lipid accumulation in the adrenal glands, liver, intestines, neurons, and brain macrophages.
The present patient, deficient in peripheral blood leukocyte and fibroblast acid lipase enzyme activity, experienced identical symptoms early in life and was admitted to receive hyperalimentation. Liver biopsy and microscopic assessment revealed minimal periportal fibrosis. Hepatocytes showed pale, vacuolated cytoplasm positive by oil red O stain. Sudan black stain and electron microscopy showed intracytoplasmic clefts consistent with cholesteryl ester accumulation.
Bone marrow transplantation was performed on 1 August 1996 at 6. months of age from an unrelated donor matching at five of six HLA loci. The recipient was A30 (19) and donor was A29 (19) . The donor had normal leukocyte acid lipase enzyme activity level of 59 nmol/mg protein/h. The preparative regimen included cyclophosphamide 60 mg/kg once daily i.v. on days −4 and −5 (total dose 120 mg/kg).
Bone Marrow Transplantation
Subtotal body irradiation was given on days −3, −2, −1 and 0 in seven fractions of 175 cGy each. 8 The brain was totally shielded. The lungs and liver were partially shielded. Irradiation was delivered with a linear accelerator using 6 MV photons, at a dose rate of 11 cGy/min. The estimated doses to shielded areas are as follows: brain 0 cGy, lung 700, liver 1050 cGy. After each fraction of radiation, the blocked areas of the calvarium, which excluded the brain, received 200 cGy electron irradiation to a total dosage of 1400 cGy in seven fractions.
Anti-thymocyte-globulin (Upjohn, Kalamazoo, MI, USA) (15 mg/kg/ dose) was given every 12 h on days −2, −1, +1, and +2 with methylprednisolone 1 mg/kg i.v. with each dose of ATG. The hematopoietic donor stem cell graft was depleted of T lymphocytes by counterflow elutriation. 9 The volume was 40 ml with a NC/kg 4.10 × 10 7 , a CD34/kg count of 6.51 × 10 6 and a CD3/kg count of 2.11 × 10 6 . This was infused 12 h after the final radiation fraction on day 0.
Graft-versus-host disease (GVHD) prophylaxis consisted of methylprednisolone and cyclosporin. The patient engrafted rapidly. The absolute neutrophil count was over 1000 cells/l for 3 days by day +18. Restriction fragment length polymorphism (RFLP) revealed 97% donor cell engraftment by day +21 reaching 100% by day +67. 10 The RFLP levels of both monocytes and neutrophils have remained at 100% level of engraftment. The leukocyte lysosomal acid lipase enzyme activity level was 50% of the normal control at day +21, remained in the 80-90% of the normal control for 2 years, and is now considered normal.
Grade II skin GVHD was confirmed histologically on day +21. She was treated with anti-thymocyte globulin 15 mg/kg i.v. for 10 doses over 5 days and pulse doses of methylprednisolone. Significant hyperbilirubinemia (peak total and direct bilirubin levels: 54.4 and 45.8 mg/dl, respectively) developed at 7 weeks from BMT. There was no evidence of hemolysis. Due to significant hypertension and elevated blood urea nitrogen, cyclosporin was discontinued. Skin manifestations slowly resolved over the following 12 months.
A significant triglyceridemia (peak: 1161 mg/dl at 2 months post BMT) and hypercholesterolemia (peak: 1099 mg/dl at 1 month post-BMT) accompanied the hyperbilirubinemia. The levels of triglycerides and cholesterol gradually returned to near normal levels by 18 months post-BMT and have subsequently remained within the normal range. At the latest visit at 4 years of age, the cholesterol level was 153 mg/dl and cholesterol was 179 mg/dl.
At day +34 and day +50 liver biopsies showed minimal centrolobular cholestasis, rare hyaline bodies, and apoptotic cells in the biliary epithelium suggestive, but not diagnostic of GVHD. On day +88, interlobular bile duct injury was consistent with GVHD. Treatment continued during this time period with methylprednisolone. Currently, 4 years after transplant, there has been no evidence of liver dysfunction. The size of the liver is normal. The bilirubin was 0.4 mg/dl, alkaline phosphatase was 212 U/l and alanine transferase was 16 U/l at the latest visit.
The severe diarrhea present before transplant worsened during the peri-transplant period. Subsequently, this gradually decreased and resolved by day +200. The stool pattern and consistency has been normal ever since day +300. Significant improvement in appetite has occurred during the past 6 months. At age 4 years she weighs 10.8 kg.
Two and a half years after BMT, severe autoimmune hemolytic anemia developed with a hemoglobin of 5.8 gm/dl, reticulocyte count of 16.8%, MCV of 103 fl, Coombs positive (C3 and IgG), and evidence of RBC destruction on review of the peripheral blood smear. The hemolysis was effectively treated by methylprednisolone 2 mg/kg/day i.v. and dexamethasone 25 mg/m 2 /day for 4 days every 4 weeks. There has been no recurrence for the last 1. years off specific therapy for hemolysis. Immunoglobulins (G, A, M, E) are within normal limits.
The adrenal calcifications remain as prior to the transplant. Initially, in the first few months, the adrenal function tests were normal. Several ACTH stimulation tests were administered. The level of fasting cortisol ranged from 4-16 g/dl and the 60-min levels were 15-37 g/dl. ACTH stimulation tests done at 1 year and again 2 years after BMT were abnormal. Fasting cortisol levels were 2-4 g/dl and the 60-min levels were 4 g/dl and 0 g/dl.
Before and immediately after transplantation there was considerable developmental delay. However, during the last 6 months there has been continued language development in both English and Spanish. Motor function has improved so that she is now learning to tap dance. She is socially alert and attentive and attends special school. The conclusion reached at the present time is that there has been some improvement in cognitive function.
Mutation analysis
Both the affected brother, who died, and our transplanted patient, who is in remission from the disease, had identical acid lipase gene mutations of fibroblasts (347GϾA/stop codon; 724delT). 11 Their mother had the latter and father the former mutations.
Leukocyte acid lipase levels
Their mother and father had leukocyte levels of lysosomal acid lipase which were significantly depressed using both trioleate and cholesterol-oleate substrates (8 and 17, respectively with average normal values of 82-239 nmol/mg protein/h). Our transplanted patient had levels of 0 using both substrates. At the latest visit at 4 years of age, the leukocyte lysosomal acid lipase levels were considered 100% of normal values.
Discussion
The rationale for anticipating a positive result from allogeneic bone marrow transplantation was based on several experiments. Acid lipase enzyme could be secreted and appropriately endocytosed in vitro into abnormal Wolman fibroblasts by co-culturing them with normal fibroblasts. 3 Similar results, in a murine mouse model, had been obtained in vivo following correction of the acid lipase deficiency after bone marrow transplantation. 5 We had also seen engraftment in four other Wolman dis-ease patients following bone marrow transplantation. 6 Their leukocyte lysosomal acid lipase levels normalized. In our review of these patients, we observed improvement in the pathological findings compared to non-transplanted patients with Wolman disease. This included reduction in the accumulation of lipid laden cells in the intestine, liver and lungs.
These observations provided us with sufficient data to undertake an allogeneic bone marrow transplant in this patient following approval by the Institutional Review Board of the University of Minnesota.
As a result of allogeneic bone marrow transplantation and engraftment from a normal donor, a source of normal leukocyte lysosomal acid lipase for this patient has been present for 3. years. The severe diarrhea originally present has resolved. Liver dysfunction leading to fibrosis has not occurred. Death, as occurred in her sibling due to similar symptoms which led eventually to pulmonary fibrosis, has been prevented. Both siblings had identical mutation analysis indicative of equivalent genomic defects. We may conclude that bone marrow transplantation has been successful in halting the progression of the major causes of demise ascribed to Wolman disease.
Significant GVHD and veno-occlusive disease was the cause of death in the four patients presented in Ref 6 . We believe that our present protocol has ameliorated these complications allowing survival of graft and patient. Busulfan and cyclophosphamide as previously used in several of our patients may have been the cause of demise and could possibly cause significant veno-occlusive disease.
We have also learned that liver transplantation should not be undertaken. In Wolman disease the presence or potential for hepatic fibrosis had been considered by some to be a rationale for either orthotopic or parental partial liver transplantation. Review of one of our patients who had a liver transplant prior to bone marrow transplant has been published. 6 Despite the liver transplant, excessive lipid deposition in the lungs and recurrent cirrhosis in the donor liver occurred. The ensuing delay in performing the bone marrow transplant was considered a cause of treatment failure in that patient.
Clinical data from other diseases suggest that bone marrow transplantation may halt progression of hepatic fibrosis. The experience in a large series of patients transplanted for thalassemia is instructive. There is abundant literature to indicate that fibrosis is ameliorated and may even resolve completely after bone marrow transplant. Severe and moderate degrees of fibrosis can be reduced to mild and absent in many patients as shown by biopsy before transplant and after several years of engraftment. 12 Similarly, in a prospective study of 111 children undergoing bone marrow transplant, serial liver function tests and follow-up indicated only a low incidence (3.6%) of severe hepatic complications. 13 An event-free survival rate of 50% was noted in the most advanced group of thalassemic patients.
14 These have significant degrees of hepatitis and fibrosis in original biopsies before transplant. Later biopsies indicate clearing of initial pathology after successful bone marrow transplantation. We would equate the pathogenesis of such fibrosis in thalassemia due to iron with the potential toxicity of the lipid overload in the hepatocytes in Wolman disease.
Bone Marrow Transplantation
Another disease, Niemann-Pick Type C, is characterized by lipid accumulation leading to cirrhosis and early death. A patient with Niemann-Pick Type C has been treated with bone marrow transplant with engraftment. 15 In this latter report, the expected progression to cirrhosis has not occurred after 2 years.
All of the above evidence would suggest that fibrosis should not be considered a contraindication to bone marrow transplantation in Wolman disease. Our experience would indicate that waiting for liver transplant, be it a total liver graft from a cadaver or a partial liver transplant from a parent, is not warranted.
Delay in beginning planning for allogeneic bone marrow transplantation may also be ascribed to diagnostic problems of distinguishing Wolman disease from cholesteryl storage disease. Wolman disease begins very early in life and is always associated with adrenal calcification. The classic cholesteryl storage disease has a peak incidence of onset later in childhood and is rarely associated with adrenal calcification. 4 There has been extensive investigation into the pathophysiology of these lipid disorders. [16] [17] [18] [19] [20] [21] Anderson and others provide documentation by mutation analysis which differentiates Wolman disease from cholesteryl storage disease.
We have previously noted that therapy recommended for cholesteryl storage disease includes cholesterol synthesis inhibitors such as the statins; such therapy is probably unwarranted in Wolman disease. 6 The rationale is that this causes an elevation of the cholesterol and triglyceride levels and alkaline phosphatases.
We believe that use of radiation provides more secure engraftment and at the same time prevents neurotoxicity to the brain.
We are hopeful that the present patient's trend of weight gain and improved developmental milestones will continue.
